Moderna Management

Management criteria checks 2/4

Moderna's CEO is Stephane Bancel, appointed in Oct 2011, has a tenure of 11.42 years. total yearly compensation is $18.16M, comprised of 5.5% salary and 94.5% bonuses, including company stock and options. directly owns 5.44% of the company’s shares, worth CHF2.68B. The average tenure of the management team and the board of directors is 3.4 years and 8.8 years respectively.

Key information

Stephane Bancel

Chief executive officer

US$18.2m

Total compensation

CEO salary percentage	5.5%
CEO tenure	11.4yrs
CEO ownership	5.4%
Management average tenure	3.4yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stephane Bancel's remuneration changed compared to Moderna's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	US$8b
Sep 30 2022	n/a	n/a	US$12b
Jun 30 2022	n/a	n/a	US$14b
Mar 31 2022	n/a	n/a	US$15b
Dec 31 2021	US$18m	US$990k	US$12b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$3b
Mar 31 2021	n/a	n/a	US$598m
Dec 31 2020	US$13m	US$946k	-US$747m
Sep 30 2020	n/a	n/a	-US$597m
Jun 30 2020	n/a	n/a	-US$488m
Mar 31 2020	n/a	n/a	-US$505m
Dec 31 2019	US$9m	US$921k	-US$514m
Sep 30 2019	n/a	n/a	-US$535m
Jun 30 2019	n/a	n/a	-US$499m
Mar 31 2019	n/a	n/a	-US$459m
Dec 31 2018	US$59m	US$863k	-US$402m
Sep 30 2018	n/a	n/a	-US$299m
Jun 30 2018	n/a	n/a	-US$280m
Mar 31 2018	n/a	n/a	-US$266m
Dec 31 2017	US$7m	US$651k	-US$270m

Compensation vs Market: Stephane's total compensation ($USD18.16M) is above average for companies of similar size in the Swiss market ($USD6.38M).

Compensation vs Earnings: Stephane's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Stephane Bancel (49 yo)

11.4yrs

Tenure

US$18,155,739

Compensation

Mr. Stephane Bancel serves as Board Director of Indigo Agriculture Inc since 2020. Mr Bancel serves as Interim President of Valera LLC. Mr. Bancel serves as a Special Partner at Flagship Pioneering since F...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Noubar Afeyan	Co-Founder	13.2yrs	US$1.63m	0.57% $ 278.7m
Stephane Bancel	CEO & Director	11.4yrs	US$18.16m	5.44% $ 2.7b
Stephen Hoge	President	no data	US$7.80m	0.46% $ 227.6m
Shannon Klinger	Chief Legal Officer & Corporate Secretary	1.8yrs	US$11.76m	0.0015% $ 743.3k
Juan Andres	President of Strategic Partnerships & Enterprise Expansion	5.6yrs	US$6.60m	0.0033% $ 1.6m
James Mock	Chief Financial Officer	less than a year	no data	no data
Jerh Collins	Chief Technical Operations & Quality Officer	less than a year	no data	no data
Melissa Moore	Chief Scientific Officer & Member of Scientific Advisory Board	6.4yrs	no data	no data
Brad Miller	Chief Information Officer	less than a year	no data	no data
Lavina Talukdar	Senior VP & Head of Investor Relations	3.9yrs	no data	no data
Colleen Hussey	Senior Director of Corporate Communications	no data	no data	no data
Tracey Franklin	Chief Human Resources Officer	3.4yrs	no data	no data

3.4yrs

Average Tenure

49yo

Average Age

Experienced Management: 0QF's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Noubar Afeyan	Co-Founder	13.2yrs	US$1.63m	0.57% $ 278.7m
Stephane Bancel	CEO & Director	12yrs	US$18.16m	5.44% $ 2.7b
Melissa Moore	Chief Scientific Officer & Member of Scientific Advisory Board	no data	no data	no data
Elizabeth Tallett	Independent Director	2.7yrs	US$594.93k	0.00018% $ 88.6k
Robert Langer	Independent Non Executive Director & Member of Scientific Advisory Board	12.3yrs	US$586.80k	2.98% $ 1.5b
Scott Canute	Member of Technology Advisory Board	8.8yrs	no data	no data
Elizabeth Nabel	Independent Director	2yrs	US$633.39k	0.00018% $ 88.6k
Fred Regnier	Member of Technology Advisory Board	8.8yrs	no data	no data
Ulrich von Andrian-Werburg	Member of Scientific Advisory Board	no data	no data	no data
Jack Szostak	Chairman of Scientific Advisory Board	8.8yrs	no data	no data
John Aunins	Member of Technology Advisory Board	8.8yrs	no data	no data
Stephen Berenson	Independent Non Executive Director	5.4yrs	US$591.43k	0.0054% $ 2.6m

8.8yrs

Average Tenure

61yo

Average Age

Experienced Board: 0QF's board of directors are considered experienced (8.8 years average tenure).

Moderna Management

Management criteria checks 2/4

Key information

Recent management updates

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. Announces Executive Changes

Moderna, Inc. Announces Management Changes

Recent updates

Moderna, Inc. to Report Q1, 2024 Results on May 02, 2024

Arbutus Biopharma Announces Claim Construction Ruling in Its Ongoing Patent Infringement Lawsuit Against Moderna

Moderna, Inc. Advances Multiple Vaccine Programs to Late-Stage Clinical Trials

Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine

Moderna, Inc., Annual General Meeting, May 06, 2024

Moderna, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Moderna, Inc. Reiterates Earnings Guidance for the Year 2024, 2025 and 2026

Moderna Announces Changes to Commercial Organization

Moderna Announces Changes to Commercial Organization

Moderna, Inc. Provides Sales Guidance for the Year 2023

Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine against Influenza and COVID-19

Moderna, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Moderna, Inc. Announces Positive Phase 1/2 Data from mRNA-1083, the company's Combination Vaccine Against Influenza and COVID-19

Moderna, Inc. Announces Ema Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's Updated Covid-19 Vaccine in the European Union

Moderna Receives U.S. FDA Approval for Updated Covid-19 Vaccine

Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against Ba.2.86

Moderna Clinical Trial Data Confirm its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

UMass Chan Medical School Announces Enrollment in Study to Explore Impact of Cytomegalovirus (CMV) Transmission in Early Education Settings

Moderna, Inc. Provides Sales Guidance for the Full Year 2023

Merck and Moderna, Inc. Initiate Phase 3 Study Evaluating V940 (Mrna-4157) in Combination with Keytruda(R) (Pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage Iib-Iv) Melanoma

Moderna, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Moderna Announces Global Regulatory Submissions for its Respiratory Syncytial Virus (RSV) Vaccine, mRNA-1345

Moderna, Inc. Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine

Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell Top 200 Growth Index

Moderna, Inc. Completes Submission of A Regulatory Application to the U.S. Food and Drug Administration for Its Updated COVID-19 Vaccine Containing Spike Proteins for the XBB.1.5 Sublineage of SARS-CoV-2

Moderna and Merck Announces mRNA-4157 (V940) in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

Moderna, Inc. Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate

Moderna, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Moderna, Inc. (NasdaqGS:MRNA) entered into a definitive agreement to acquire OriCiro Genomics, Inc for $85 million.

Chantal Friebertshäuser Joins Moderna, Inc. as Senior Vice President of Commercial - Europe, Middle East and Canada, Effective January 1, 2023

Moderna, Inc. and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Investor sentiment improved over the past week

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Moderna, Inc. Announces Executive Changes

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Moderna, Inc. Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster

Third quarter 2022 earnings released: EPS: US$2.67 (vs US$8.25 in 3Q 2021)

Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222

Investor sentiment improved over the past week

Moderna, Inc. Announces EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union

Moderna, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Moderna, Inc. Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Investor sentiment improved over the past week

Moderna, Inc. Announces Management Changes

European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine

Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EMA Committee for Medicinal Products for Human Use (Chmp) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union

Moderna, Inc. Announces Swissmedic Authorizes its Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214

Moderna, Inc. Announces Executive Changes

Moderna, Inc. Announces Medicines and Healthcare Products Regulatory Agency Authorizes Omicron-Containing Bivalent Booster in the Uk

Moderna, Inc. Fires Jorge Gomez as CFO

Moderna, Inc. Appoints Arpa Garay as Chief Commercial Officer, Effective May 31, 2022

Moderna, Inc. to Report Q1, 2022 Results on May 04, 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age